Abstract:Background Targeted next-generation sequencing (NGS) is increasingly applied in clinical oncology to advance personalized treatment. Despite success in many other tumour types, use of targeted NGS panels for assisting diagnosis and treatment of head and neck squamous cell carcinomas (HNSCC) is still limited. Aim The focus of this study was to establish a robust NGS panel targeting most frequent cancer mutations in long-term preserved formalin-fixed paraffin-embedded (FFPE) tissue samples of HNSCC from routine diagnostics. Materials and Methods Tumour DNA obtained from archival FFPE tissue blocks of HNSCC patients treated at Haukeland University Hospital between 2003-2016 (n=111) was subjected to mutational analysis using a custom made AmpliSeq Library PLUS panel targeting 31 genes (Illumina). Associations between mutational burden and clinical and pathological parameters were investigated. Mutation and corresponding clinicopathological data from HNSCC were extracted for selected genes from the Cancer Genome Atlas (TCGA) and used for Chi-square and Kaplan-Meier analysis. Results The threshold for sufficient number of reads was attained in 104 (93.7%) cases. Although the specific number of PCR amplified reads detected decreased, the number of NGS-annotated mutations did not significantly change with increased tissue preservation time. In HPV-negative carcinomas, mutations were detected mainly in TP53 (73.3%), FAT1 (26.7%) and FLG (16.7%) whereas in HPV-positive, the common mutations were in FLG (24.3%) FAT1 (17%) and FGFR3 (14.6%) genes. Other less common pathogenic mutations, including well reported SNPs were reproducibly identified. Presence of at least one cancer-specific mutations was found to be positively associated with an extensive desmoplastic stroma (p=0.019), and an aggressive type of invasive front (p=0.035), and negatively associated with the degree of differentiation (p=0.041). Analysis of TCGA data corroborated the association between cancer-specific mutations and tumour differentiation and survival analysis showed that tumours with at least one mutation had shorter disease-free and overall survival (p=0.005). Conclusions A custom made targeted NGS panel could reliably detect several specific mutations in archival samples of HNSCCs preserved up to 17 years. Using this method novel associations between mutational burden and clinical and pathological parameters were detected and actionable mutations in HPV-positive HNSCC were discovered.

The TP53 Codon 72 Arginine Polymorphism Is Found with Increased TP53 Somatic Mutations in HPV(−) and in an Increased Percentage among HPV(+) Norwegian HNSCC Patients

Associations of TP53 Mutations, Codon 72 Polymorphism and Human Papillomavirus in Head and Neck Squamous Cell Carcinoma Patients.

P53 Codon 72 Polymorphism in Cervical Cancers and Its Correlation with HPV16,18E6

Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program

Association of TP53 Codon 72 Polymorphism with Cervical Cancer Risk in Chinese Women

p53 Codon 72 polymorphism is associated with occurrence of cervical carcinoma in the Chinese population.

Analyzation of TP53 Expression, Mutation,codon 72 Polymorphism and the Relationship with Human Papillomavirus Infection of the Chinese Laryngeal Squamous Cell Carcinoma Patients

Exploring the roles of HPV16 variants in head and neck squamous cell carcinoma: current challenges and opportunities

[Study on the Relationship Between Cervical Cancer and P53 Codon 72 Polymorphism].

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

Analysis of TP53 Mutations and HPV Infection in Esophageal Cancer

Evaluating the Prognostic Significance of P53 and TP53 Mutations in HPV-negative Hypopharyngeal Carcinoma Patients: a 5-Year Follow-Up Retrospective Study

Association of P53 and MDM2 Polymorphisms with Risk of Human Papillomavirus (Hpv)-Related Esophageal Squamous Cell Carcinoma (ESCC).

The Prognostic Value of Human Papillomavirus Status in Penile Cancer: Outcomes From a Norwegian Cohort Study

Human Papillomavirus 16 Infection and TP53 Mutation: Two Distinct Pathogeneses for Oropharyngeal Squamous Cell Carcinoma in an Eastern Chinese Population

Association Between P53 Arg72Pro Polymorphism and the Risk of Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma: A Meta-analysis

Correlation Between P53 Codon 72 Polymorphism and Tumorigenesis of Cervical Cancer

P53 Codon 72 Polymorphism (C/G) and the Risk of Human Papillomavirus-Associated Carcinomas in China

Targeted Next-Generation Sequencing of Cancer-Related Genes in a Norwegian Patient Cohort With Head and Neck Squamous Cell Carcinoma Reveals Novel Actionable Mutations and Correlations With Pathological Parameters

Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization

Identification of Prognostic Molecular Biomarkers in 157 HPV‐positive and HPV‐negative Squamous Cell Carcinomas of the Oropharynx